A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 by Brown, N, Williams, M, Arkenau, H, Fleming, R, Tolson, J, Yan, L, Zhang, J, Swartz, L, Singh, R, Auger, K, Lenox, L, Cox, D, Lewis, Y, Plisson, C, Searle, G, Saleem, A, Blagden, S, Mulholland, P

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors by Soria, J, Gan, H, Blagden, S, Plummer, R, Arkenau, H, Ranson, M, Evans, T, Zalcman, G, Bahleda, R, Hollebecque, A, Lemech, C, Dean, E, Brown, J, Gibson, D, Peddareddigari, V, Murray, S, Nebot, N, Mazumdar, J, Swartz, L, Auger, K, Fleming, R, Singh, R, Millward, M